



Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

November 25, 2020

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.

Conference Presentation Details

Conference: Evercore ISI 3rd Annual HealthCONx

Format: Fireside chat with Umer Raffat

Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, Shattuck's Vice President of Finance and Corporate Strategy

Date: December 2, 2020

Time: 1:00 p.m. EST

Webcast Link: Available [Here](#)

The live webcast of the fireside chat will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation dates.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC[®], platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRP α -Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN[™], platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:

Conor Richardson

Director of Finance

Shattuck Labs, Inc.

InvestorRelations@shattucklabs.com

Media Contact:

Stephanie Ascher

Managing Director

Stern Investor Relations, Inc.

Stephanie.ascher@sternir.com



Source: Shattuck Labs, Inc.